Skip to main content
main-content

01.12.2017 | Study protocol | Ausgabe 1/2017 Open Access

BMC Cancer 1/2017

ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS)

Zeitschrift:
BMC Cancer > Ausgabe 1/2017
Autoren:
JV Reynolds, SR Preston, B O’Neill, L Baeksgaard, SM Griffin, C Mariette, S Cuffe, M Cunningham, T Crosby, I Parker, K Hofland, G Hanna, LB Svendsen, CL Donohoe, C Muldoon, D O’Toole, C Johnson, N Ravi, G Jones, AK Corkhill, M Illsley, J Mellor, K Lee, M Dib, V Marchesin, M Cunnane, K Scott, P Lawner, S Warren, S O’Reilly, G O’Dowd, G Leonard, B Hennessy, R Mc Dermott
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​s12885-017-3386-2) contains supplementary material, which is available to authorized users.

Abstract

Background

Neoadjuvant therapy is increasingly the standard of care in the management of locally advanced adenocarcinoma of the oesophagus and junction (AEG). In randomised controlled trials (RCTs), the MAGIC regimen of pre- and postoperative chemotherapy, and the CROSS regimen of preoperative chemotherapy combined with radiation, were superior to surgery only in RCTs that included AEG but were not powered on this cohort. No completed RCT has directly compared neoadjuvant or perioperative chemotherapy and neoadjuvant chemoradiation. The Neo-AEGIS trial, uniquely powered on AEG, and including comprehensive modern staging, compares both these regimens.

Methods

This open label, multicentre, phase III RCT randomises patients (cT2-3, N0-3, M0) in a 1:1 fashion to receive CROSS protocol (Carboplatin and Paclitaxel with concurrent radiotherapy, 41.4Gy/23Fr, over 5 weeks). The power calculation is a 10% difference in favour of CROSS, powered at 80%, two-sided alpha level of 0.05, requiring 540 patients to be evaluable, 594 to be recruited if a 10% dropout is included (297 in each group). The primary endpoint is overall survival, with a minimum 3-year follow up. Secondary endpoints include: disease free survival, recurrence rates, clinical and pathological response rates, toxicities of induction regimens, post-operative pathology and tumour regression grade, operative in-hospital complications, and health-related quality of life. The trial also affords opportunities for establishing a bio-resource of pre-treatment and resected tumour, and translational research.

Discussion

This RCT directly compares two established treatment regimens, and addresses whether radiation therapy positively impacts on overall survival compared with a standard perioperative chemotherapy regimen Sponsor: Irish Clinical Research Group (ICORG).

Trial registration

NCT01726452. Protocol 10-14. Date of registration 06/11/2012.
Zusatzmaterial
Additional file 1 Appendix A: Description of data: copy of consent form (DOCX 60 kb)
12885_2017_3386_MOESM1_ESM.docx
Additional file 2 Appendix B: - Description of data: Membership of Trials Steering Committee (DOCX 22 kb)
12885_2017_3386_MOESM2_ESM.docx
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

BMC Cancer 1/2017 Zur Ausgabe


 

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise